Skip to content

Allen & Overy advises the lending banks syndicate on a EUR451 million financing in connection with the EUROAPI’s contemplated listing on Euronext Paris

Related people
Julien Roux

Partner

Paris

View profile →

Vignon Mathieu
Mathieu Vignon

Partner

Paris

View profile →

Image of Tristan Jambu-Merlin
Tristan Jambu-Merlin

Senior Associate

Paris

View profile →

Chatte Virginie
Virginie Chatté

Senior Associate

Paris

View profile →

Image of Quitterie D'Andoque
Quitterie d'Andoque

Associate

Paris

View profile →

Press contacts

For media enquiries relating to this topic, please contact:

Amelie Gillot

Communications Officer

Paris

View profile →

08 April 2022

Allen & Overy has advised the banking syndicate, composed of BNP Paribas, Bank of America, Crédit Agricole Corporate and Investment Bank, Deutsche Bank, J.P. Morgan, Natixis and Société Générale, on a revolving credit facility provided to EUROAPI in connection with its contemplated listing on Euronext Paris.

EUROAPI’s listing on Euronext Paris aims to reinforce its status as partner of choice for all pharmaceutical laboratories and biotech companies and clarify EUROAPI’s independence from Sanofi. EUROAPI first day of trading on Euronext Paris is expected to occur on May 6.

This EUR451 million five-year revolving credit facility will help EUROAPI, a leading player in active pharmaceutical ingredients, to finance its general needs and potential future acquisitions.

The Allen & Overy team in Paris was composed of Julien Roux (Partner), Tristan Jambu-Merlin (Senior Associate) and Quitterie d'Andoque (Associate), and also included Mathieu Vignon (Partner) and Virginie Chatté (Senior Associate) on tax aspects.